Physician profile
Abiy Abebe
NPI 1154855104
$1,529.65
in general payments reported to CMS, 2019-2025
15 companies · $17.03 in 2025
The $17.03 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $178 · 2021: $204 · 2022: $213 · 2023: $571 · 2024: $347 · 2025: $17.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $640.50 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $219.25 | 2021-2024 | Lokelma, Farxiga |
| Pfizer INC. | $141.72 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $137.43 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $74.73 | 2021-2024 | |
| Novo Nordisk INC | $62.21 | 2022-2023 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $60.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.50 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $34.10 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Chiesi USA, INC. | $27.55 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.86 | 2020 | |
| Smith+Nephew, INC. | $18.23 | 2023 | Collagenase Santyl |
| Viatris Specialty LLC | $17.03 | 2025 | Yupelri |
| Mylan Specialty L.P. | $13.91 | 2022 | |
| Abbvie INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abiy Abebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.